share_log

JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $11

Benzinga ·  Oct 19, 2023 15:08

JP Morgan analyst Eric Joseph maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $31 to $11.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment